Novavax | NVAX - Ebitda

Stock Price
9.34
Daily Change
0.08 0.81%
Monthly
-16.58%
Yearly
26.32%
Q1 Forecast
9.33

Novavax reported $19.36M in EBITDA for its fiscal quarter ending in December of 2025.





Ebitda Change Date
Adma Biologics USD 73.59M 14.85M Dec/2025
Agenus USD -10.11M 19.02M Mar/2025
AstraZeneca USD 5.23B 272M Sep/2025
BioCryst Pharmaceuticals USD 51.7M 30.14M Sep/2025
Cassava Sciences USD -11.73M 33.44M Sep/2025
Geron USD -9.47M 1.92M Sep/2025
GlaxoSmithKline GBP 3.36B 179M Sep/2025
MannKind USD 17.92M 8.17M Sep/2025
Merck USD 8.39B 1.97B Sep/2025
Minerva Neurosciences USD -4.36M 1.71M Sep/2024
Moderna USD -790M 582M Dec/2025
Novartis USD 5.84B 235M Sep/2025
Novavax USD 19.36M 190.79M Dec/2025
Pfizer USD 6.08B 351M Sep/2025
Sanofi EUR 4.84B 2.95B Sep/2025
Sarepta Therapeutics USD -168.03M 294.45M Sep/2025
TG Therapeutics USD 32.69M 5M Sep/2025